Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 15

1.

A new tool for tuberculosis vaccine screening: Ex vivo Mycobacterial Growth Inhibition Assay indicates BCG-mediated protection in a murine model of tuberculosis.

Zelmer A, Tanner R, Stylianou E, Damelang T, Morris S, Izzo A, Williams A, Sharpe S, Pepponi I, Walker B, Hokey DA, McShane H, Brennan M, Fletcher H.

BMC Infect Dis. 2016 Aug 12;16:412. doi: 10.1186/s12879-016-1751-4.

2.

ESAT-6-dependent cytosolic pattern recognition drives noncognate tuberculosis control in vivo.

Kupz A, Zedler U, Stäber M, Perdomo C, Dorhoi A, Brosch R, Kaufmann SH.

J Clin Invest. 2016 Jun 1;126(6):2109-22. doi: 10.1172/JCI84978. Epub 2016 Apr 25.

PMID:
27111234
3.

Activities of Murine Peripheral Blood Lymphocytes Provide Immune Correlates That Predict Francisella tularensis Vaccine Efficacy.

De Pascalis R, Mittereder L, Kennett NJ, Elkins KL.

Infect Immun. 2016 Mar 24;84(4):1054-61. doi: 10.1128/IAI.01348-15. Print 2016 Apr.

PMID:
26810039
4.

Correlates of Vaccine-Induced Protection against Mycobacterium tuberculosis Revealed in Comparative Analyses of Lymphocyte Populations.

Kurtz SL, Elkins KL.

Clin Vaccine Immunol. 2015 Oct;22(10):1096-108. doi: 10.1128/CVI.00301-15. Epub 2015 Aug 12.

5.

Tolerance and Cross-Tolerance following Toll-Like Receptor (TLR)-4 and -9 Activation Are Mediated by IRAK-M and Modulated by IL-7 in Murine Splenocytes.

Julian MW, Strange HR, Ballinger MN, Hotchkiss RS, Papenfuss TL, Crouser ED.

PLoS One. 2015 Jul 28;10(7):e0132921. doi: 10.1371/journal.pone.0132921. eCollection 2015.

6.

Quality control and safety assessment of BCG vaccines in the post-genomic era.

Stefanova T.

Biotechnol Biotechnol Equip. 2014 May 4;28(3):387-391. Epub 2014 Jul 10. Review.

7.

Specific interaction between Mycobacterium tuberculosis lipoprotein-derived peptides and target cells inhibits mycobacterial entry in vitro.

Ocampo M, Curtidor H, Vanegas M, Patarroyo MA, Patarroyo ME.

Chem Biol Drug Des. 2014 Dec;84(6):626-41. doi: 10.1111/cbdd.12365. Epub 2014 Jul 10.

8.

Models derived from in vitro analyses of spleen, liver, and lung leukocyte functions predict vaccine efficacy against the Francisella tularensis Live Vaccine Strain (LVS).

De Pascalis R, Chou AY, Ryden P, Kennett NJ, Sjöstedt A, Elkins KL.

MBio. 2014 Apr 8;5(2):e00936. doi: 10.1128/mBio.00936-13.

9.

Time to detection of Mycobacterium tuberculosis using the MGIT 320 system correlates with colony counting in preclinical testing of new vaccines.

Kolibab K, Yang A, Parra M, Derrick SC, Morris SL.

Clin Vaccine Immunol. 2014 Mar;21(3):453-5. doi: 10.1128/CVI.00742-13. Epub 2013 Dec 26.

10.

Inhibition of mycobacterial growth in vitro following primary but not secondary vaccination with Mycobacterium bovis BCG.

Fletcher HA, Tanner R, Wallis RS, Meyer J, Manjaly ZR, Harris S, Satti I, Silver RF, Hoft D, Kampmann B, Walker KB, Dockrell HM, Fruth U, Barker L, Brennan MJ, McShane H.

Clin Vaccine Immunol. 2013 Nov;20(11):1683-9. doi: 10.1128/CVI.00427-13. Epub 2013 Aug 28.

11.

Polyclonal mucosa-associated invariant T cells have unique innate functions in bacterial infection.

Chua WJ, Truscott SM, Eickhoff CS, Blazevic A, Hoft DF, Hansen TH.

Infect Immun. 2012 Sep;80(9):3256-67. doi: 10.1128/IAI.00279-12. Epub 2012 Jul 9.

12.

Development of functional and molecular correlates of vaccine-induced protection for a model intracellular pathogen, F. tularensis LVS.

De Pascalis R, Chou AY, Bosio CM, Huang CY, Follmann DA, Elkins KL.

PLoS Pathog. 2012 Jan;8(1):e1002494. doi: 10.1371/journal.ppat.1002494. Epub 2012 Jan 19.

13.

Malaria infections do not compromise vaccine-induced immunity against tuberculosis in mice.

Parra M, Derrick SC, Yang A, Tian J, Kolibab K, Oakley M, Perera LP, Jacobs WR, Kumar S, Morris SL.

PLoS One. 2011;6(12):e28164. doi: 10.1371/journal.pone.0028164. Epub 2011 Dec 19.

14.

Comparative evaluation of profiles of antibodies to mycobacterial capsular polysaccharides in tuberculosis patients and controls stratified by HIV status.

Yu X, Prados-Rosales R, Jenny-Avital ER, Sosa K, Casadevall A, Achkar JM.

Clin Vaccine Immunol. 2012 Feb;19(2):198-208. doi: 10.1128/CVI.05550-11. Epub 2011 Dec 14.

15.

Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.

Kolibab K, Yang A, Derrick SC, Waldmann TA, Perera LP, Morris SL.

Clin Vaccine Immunol. 2010 May;17(5):793-801. doi: 10.1128/CVI.00006-10. Epub 2010 Mar 31.

Items per page

Supplemental Content

Write to the Help Desk